• Product name : SenoVue
• Brand name : Olive Healthcare Inc.
• Type : Sensory and Physical Diagnostic Device
• Model Number : BC715-WFWT
• Usage : Breast cancer diagnostic support device
• Material : Outer case made of PCABS
• Size/Dimension : Main Unit (W x D x H): 52 x 63 x 121 (cm), Probe (W x D x H): 78 x 74 x 120 (mm)
• Shelf Life : N/A
• Feature :
This device provides quantitative data of lesions in patients with suspected breast cancer, based on biological signals measured according to standard clinical guidelines.

SenoVue is a breast cancer diagnostic support device using discrete multi-wavelength near-infrared spectroscopy technology, designed to help distinguish between benign and malignant breast tumors.

It quantitatively measures and analyzes biological information (HbO₂, HHb, StO₂, Lipid, Water) in suspicious lesion areas of the breast. The results are displayed on a PC screen via dedicated software integrated with SenoVue, allowing users to visually confirm the data for clinical decision support.

• Warranty : Expected lifespan of the probe is 2 years and 3 months, but no official warranty period has been established yet.
• Certification : Currently undergoing Korean medical device approval.

SenoVue is a breast cancer imaging device for rapid breast lesion differentiation. It is quantitative and intuitive, non-invasive and radiation-free, and easy to use–helping breast cancer risk assessment. Using our most advanced near-infrared spectroscopy platform (DMW-NIRS), SenoVue is carefully designed to support the difficulty that clinicians face in today's challenging diagnostic environment.

SenoVue guides clinical decisions with precision specific to each patient and clinical situation. With its user-friendly touch-screen monitor, intuitive software, and groundbreaking DMW-NIRS technology, SenoVue helps healthcare professionals to make reliable and efficient diagnosis.

SenoVue does this by visualizing hemodynamic changes such as angiogenesis status in breast tissue suspected of lesion. It provides color maps and quantitative index to help differentiate between malignant and benign tumors in breast tissue.

SenoVue is a clinically validated imaging device. Integrating DMW-NIRS findings with ultrasound evaluations enhances diagnostic accuracy, particularly for BI-RADS 4A lesions. This novel device offers a rapid, non-invasive, and efficient method to reduce unnecessary biopsies and improve breast cancer diagnostics.